Vertical Aerospace Ltd (EVTL) Stock Message Board

Play Episode

5min

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Tamboran Resources boosts NT gas supply with Arafura deal

Tamboran Resources Ltd CEO Joel Riddle talked with Proactive about the company's newly signed letter of intent (LOI) with Arafura Resources Ltd to supply gas from the Beetaloo Basin. Riddle explained that both companies are based in the Northern Territory, and the agreement supports local strategic projects by providing 25 terajoules (TJs) per day to Arafura's critical minerals project. The agreement aligns with Tamboran’s strategy of prioritising Northern Territory gas use. “We’re a Northern Territory company. We’ve been focused on appraising the Beetaloo Basin now for all 12 years I’ve been in my job,” Riddle said, highlighting the company’s long-term commitment to the region. Riddle also pointed out the environmental edge of Beetaloo Basin gas, which has a CO2 content of about 3%, significantly lower than the 15–20% typically found in other Australian basins. He said supplying this low-carbon gas to the East Coast would help reduce emissions by displacing higher-carbon alternatives. Discussing supply capacity, Riddle compared the Beetaloo to the Marcellus Shale in the US, noting it could provide enough gas to support the East Coast for “hundreds of years”. Tamboran plans to bring 40 TJs per day online in the first half of next year under an existing 15-year agreement with the NT Government. The Arafura deal will add a further 25 TJs daily. Riddle said work is underway with pipeline partner APA to ensure infrastructure capacity. The company aims to finalise a binding gas sales agreement with Arafura soon. Watch the full interview to hear how Tamboran is positioning Beetaloo gas as a key part of the East Coast supply solution, while supporting Northern Territory industry. 👉 For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and hit the notification bell for future content. #TamboranResources #BeetalooBasin #LowCarbonGas #GasSupply #ArafuraResources #EastCoastEnergy #NorthernTerritory #CriticalMiner

Proactive - Interviews for investors

Lithium ION Energy secures joint venture with SureFQ to advance Urgakh Naran Lithium project

Lithium ION Energy Limited CEO Ali Haji joined Steve Darling from Proactive to announce a binding Joint Venture Agreement with SureFQ for the advancement of the Urgakh Naran lithium project in Mongolia. Under the agreement, ION will retain a 20% free carried interest through to commercial production, ensuring long-term participation in the project's success without additional financial commitments. SureFQ, a firm specializing in sustainable energy solutions and lithium resource development, will leverage its industry expertise and advanced extraction technologies to accelerate the project’s progress. As a strategic investor, SureFQ focuses on developing high-potential assets that support the global energy transition. Haji told Proactive SureFQ will provide $5.5 million in cash considerations to ION over 4.5 years. The company has committed to $8 million in development expenditures for Urgakh Naran over four years. ION Energy will maintain a 2.5% Net Smelter Return (NSR) royalty in perpetuity, ensuring a steady revenue stream from future production. Haji emphasized that ION Energy is a proven Direct Lithium Extraction (DLE) operator, focused on deploying modular extraction capacity to optimize efficiency. This partnership positions Urgakh Naran as a key lithium asset in Mongolia, furthering ION’s role in the global battery metals supply chain. #proactiveinvestors #lithiumionenergylimited #tsxv #ion #urgakhnaran #mongolia #lithium #IonEnergy #AliHaji #UrgakhNaran #SureFQ #MongoliaMining #LithiumExtraction #DLETechnology #BatteryMetals #EVSupplyChain #CriticalMinerals #MiningInvestment #ProactiveInvestors #JuniorMining

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Followers	12	Posters	19
Posts (Today)	1	Posts (Total)	80
Created	12/22/21	Type	Free
Moderators

Volume:	395,258
Day Range:	2.80 - 3.04
Last Trade Time:	7:51:00 PM EDT

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Vertical Aerospace Ltd (EVTL)

EVTL Detailed Quote

EVTL Latest News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Vertical Aerospace Ltd (EVTL)

EVTL Latest News

Go Ad-Free